<SEC-DOCUMENT>0001213900-25-113643.txt : 20251121
<SEC-HEADER>0001213900-25-113643.hdr.sgml : 20251121
<ACCEPTANCE-DATETIME>20251121163244
ACCESSION NUMBER:		0001213900-25-113643
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251121
DATE AS OF CHANGE:		20251121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Can-Fite BioPharma Ltd.
		CENTRAL INDEX KEY:			0001536196
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288890
		FILM NUMBER:		251508472

	BUSINESS ADDRESS:	
		STREET 1:		26 BEN GURION STREET
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5257346
		BUSINESS PHONE:		972 39241114

	MAIL ADDRESS:	
		STREET 1:		26 BEN GURION STREET
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5257346
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea0266572-424b3_canfite.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-288890</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To Prospectus dated July 28, 2025)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Up to 1,250,000&nbsp;American
Depositary Shares Representing 375,000,000&nbsp;Ordinary Shares and<BR>
accompanying 2,500,000&nbsp;Common Warrants to Purchase up to 2,500,000&nbsp;American Depositary Shares<BR>
Representing 750,000,000&nbsp;Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Up to&nbsp;7,083,333
Pre-Funded Warrants to Purchase up to 7,083,333&nbsp;American Depositary Shares<BR>
Representing 2,124,999,900&nbsp;Ordinary Shares and accompanying 14,166,666 Common Warrants to Purchase up to&nbsp;14,166,666 American
Depositary Shares Representing 4,249,999,800&nbsp;Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Up to 583,333&nbsp;Placement
Agent Warrants to Purchase up to 583,333&nbsp;American Depositary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Representing 174,999,900&nbsp;Ordinary
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to&nbsp;24,333,332 American Depositary Shares
Representing 7,299,999,600&nbsp;Ordinary Shares Issuable Upon</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercise of the Common Warrants, Pre-Funded Warrants and Placement Agent
Warrants</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Can-Fite Biopharma Ltd.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus supplement updates, amends and
supplements the prospectus dated July 28, 2025 (as supplemented or amended from time to time, the &ldquo;Prospectus&rdquo;), which
forms a part of our Registration Statement on Form F-1 (Registration No. 333-288890). This prospectus supplement is being filed to
update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our
Report on Form 6-K, which was furnished to the Securities and Exchange Commission on November 21, 2025. Accordingly, we have
attached the&nbsp;Form&nbsp;6-K&nbsp;to this prospectus supplement. Capitalized terms used in this prospectus supplement and not
otherwise defined herein have the meanings specified in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement is not complete without
the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus
supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or
supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ADSs are listed on NYSE American under the symbol
&ldquo;CANF.&rdquo; On November 19, 2025, the closing price of our ADSs on the NYSE American was $0.33 per ADS. Our Ordinary Shares also
trade on the Tel Aviv Stock Exchange, or TASE, under the symbol &ldquo;CFBI&rdquo;. On November 19, 2025, the sale price of our Ordinary
Shares on the TASE was NIS 0.01 or $0.00306 per share (based on the exchange rate reported by the Bank of Israel on the same day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 7 of the Prospectus and other risk factors contained in the documents
incorporated by reference therein, including the risks described under &ldquo;Risk Factors&rdquo; in our Annual Report on Form 20-F for
the year ended December 31, 2024, for a discussion of information that should be considered in connection with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission,
the Israeli Securities Authority nor any state securities commission has approved or disapproved of these securities or determined if
the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of January 9, 2023, the ratio of
our ADSs to Ordinary Shares changed from one (1) ADS representing thirty (30) Ordinary Shares to a new ratio of one (1) ADS representing
three hundred (300) Ordinary Shares, which ratio change had the same effect as a one-for-ten reverse ADS split (the &ldquo;ADS Ratio Change&rdquo;).
All share and per share prices in this prospectus supplement have been adjusted to reflect the ADS Ratio Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is November
21, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of November 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">001-36203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAN-FITE BIOPHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>26 Ben Gurion Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ramat Gan 5257346 Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Report of Foreign Private Issuer on Form
6-K is hereby incorporated by reference into the registrant&rsquo;s Registration Statements on Form S-8 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1536196/000121390018013702/fs82018_canfitebiopharma.htm">333-227753</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1536196/000121390023031683/ea176911-s8_canfitebiopharma.htm">333-271384</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1536196/000121390024030834/ea0203150-s8_canfitebio.htm">333-278525</A>)
and Form F-3 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1536196/000121390020008630/ea120459-posam_canfitebio.htm">333-236064</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1536196/000121390023073236/ea184383-f3_canfite.htm">333-274316</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1536196/000121390022001135/ea153627-f3_canfite.htm">333-262055</A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1536196/000121390023095107/ea189833-f3_canfite.htm">333-276000</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1536196/000121390024074545/ea0211728-f3_canfite.htm">333-281872</A>),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2025, Can-Fite BioPharma Ltd.
(the &ldquo;Company&rdquo;) entered into an agreement with the holder of warrants to purchase 16,666,666 American Depositary Shares (&ldquo;ADSs&rdquo;)
previously issued on July 29, 2025, pursuant to which in consideration for the holder&rsquo;s waiver of certain standstill provisions,
the Company reduced the exercise price of such warrants from $0.60 per ADS to $0.467 per ADS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: November 21, 2025</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font-size: 10pt">/s/ Motti Farbstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Motti Farbstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer and <BR>
Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 2L# 2(  A$! Q$!_\0
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MJ]QKFGV,)GNY](E6*,,%W'S8CC)( Z=S6TH12V ?_P ++\:?]##<_P#?N/\
M^)H_X67XT_Z&&Y_[]Q__ !-3_P#"J_''_0OR?^!4'_Q=5-1^'WBW2-.GO[[1
MG@M8%W2R&XB;:/7 <D_@*/W?D!)_PLKQI_T,-S_W[C_^)H_X65XT_P"AAN?^
M_<?_ ,37*U;TS3+W6=2@T_3X#<7DY(CB#*N["ECRQ ' )Y/:CDCV&;__  LO
MQI_T,-S_ -^X_P#XFM'0/B#XNN]7$-QKMP\?V:Z?:4C^\MM*ZGA>S*#^%5/^
M%5^./^A?D_\  J#_ .+J[I'@#Q5HM[-J6I:.]O9P6-V9)3/$VW-M*HX5R>I
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MG%ID3XGU*7:P'7RDPS?KL'T8U\^UUX>.G,-':_"?1O[8^(-B77=#8JUV^?\
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M2G:'_OS?^B)*X^NP^%7_ "4[0_\ ?F_]$25Z$_A91]25B^+?^1.US_L'S_\
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M9'5E=2596&"I'4$=C752FI1L!],_#3Q);:_X+LT$JF[L8DM[F+/S*5&%8^S
M9STZCL:[FOC.ROKO3KI;JQNY[6X48$L$A1@.XR.WM6I?>+_$FI6S6UYKE_)
MPVM&9B%8>A QD?6LY8=MZ,+'4?%CQ7'KGBZ&+3K@FWTM6CCGB;&96(WE6'88
M49]5/:LW2/B?XPT?:JZH;R(?\LKY?-S_ ,"X?_QZN.Z# K1TW2I;VWO;YU9;
M&PB\RXEQQN/"1@_WF8@>PR>U;>SBHV8R_P"+O%MYXRU>'4+N%(#' L2Q1L2H
MP221GU)_0>E<_1VK;\)^'9?%?B2VT>&?[/YP=GF\O>(U52<XR,\X'7O6FE-
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M47_H8KJG%2BTRHR<7>+U/5?%G@O0_ 6E1ZQ-'=ZINN%BBM9YE2/<58@N57)
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M@FCFAD>*6-@Z21L596!R"".00>]>HU>-BC[0HKY#_P"$I\2?]#'K'_@?+_\
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MAAV"_K6'_P *"O\ _H8;;_P$;_XNO=,T5HJLTK)A<\+_ .%!7_\ T,-M_P"
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M.EW/V6_UO3K6XP#Y4]TB-@]#@G-9V8CR4? *_P ?\C#;?^ C?_%TO_"@K_\
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M-,"(DI]^'[N><<#'M7HWBKP=H.H^,+.XN;$F:[4)</'/)&95R%PVUAGY>/H
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.U%E? S*Y]?>JYM /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
